Our approach is based on a wide range of activities: ▪ Conducting environmental risk assessments of all active pharmaceutical ingredients (APIs) used in our products prior to market approval to determine potential environmental concentration and risks; ▪ Monitoring our manufacturing wastewaters for potential toxicity to aquatic species, and controlling our discharges according to local regulations; ▪ Employing sourcing practices that help ensure that our chemical and API suppliers comply with our expectations for environmental and social practices; ▪ Proactive partnering with stakeholders across the healthcare sector; ▪ Advancing the science on this issue through company-directed research and public-private research consortiums.